【Dayeh Biomedical】Report on the Completion of Share Buyback Period

Key facts

  • 【Dayeh Biomedical】Report on the Completion of Share Buyback Period
  • Dayeh Biomedical executed a share buyback from March 31 to May 25, 115. Out of the planned 7.5 million shares, 4.46 million were repurchased at an average price of 18.48 TWD, totaling 82.41 million TWD. The shortfall was due to a phased buyback strategy to maintain market stability.
  • Source: PR Times
  • Date: May 25, 2026

Direct answer

Dayeh Biomedical executed a share buyback from March 31 to May 25, 115. Out of the planned 7.5 million shares, 4.46 million were repurchased at an average price of 18.48 TWD, totaling 82.41 million TWD. The shortfall was due to a phased buyback strategy to maintain market stability.

Citation
【Dayeh Biomedical】Report on the Completion of Share Buyback Period (May 25, 2026), PR Times
Source
PR Times
Date
May 25, 2026
Dayeh Biomedical executed a share buyback from March 31 to May 25, 115. Out of the planned 7.5 million shares, 4.46 million were repurchased at an average price of 18.48 TWD, totaling 82.41 million TWD. The shortfall was due to a phased buyback strategy to maintain market stability.
financeNQ 44/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: May 25, 2026 at 09:00
  • 🔍 Collected: May 26, 2026 at 08:00 (23h 0m after Published)
  • 🤖 AI Analyzed: May 31, 2026 at 20:07 (132h 7m after Collected)
1. Original max buyback amount: 4,474,756,140 TWD. 2. Original period: 115/03/26~115/05/25. 3. Original target quantity: 7,500,000 shares. 4. Price range: 12.75~33.80 TWD. 5. Actual period: 115/03/31~115/05/25. 6. Actual quantity repurchased: 4,460,000 shares. 7. Total amount spent: 82,408,946 TWD. 8. Average price per share: 18.48 TWD. 9. Cumulative shares held: 4,460,000 shares. 10. Percentage of total issued shares: 0.55%. 11. Reason for incomplete execution: To balance market mechanisms and shareholder interests, the company adopted a phased buyback strategy based on stock price and volume. 12. Other: None.

FAQ

What is the result of Dayeh Biomedical's buyback?

They repurchased 4.46 million shares for approximately 82.41 million TWD.

What are the key facts in this article?

Dayeh Biomedical executed a share buyback from March 31 to May 25, 115. Out of the planned 7.5 million shares, 4.46 million were repurchased at an average price of 18.48 TWD, totaling 82.41 million TWD. The shortfall was due to a phased buyback strategy to maintain market stability.

What is the direct answer?

Dayeh Biomedical executed a share buyback from March 31 to May 25, 115. Out of the planned 7.5 million shares, 4.46 million were repurchased at an average price of 18.48 TWD, totaling 82.41 million TWD. The shortfall was due to a phased buyback strategy to maintain market stability.

Back to Newsroom (72)